Oncoinvent ASA (0RU5)
LSE
Closed
Oct 6, 2026
Day's Range
79.0052 wk Range
0.4400Overview - 0RU5 - Oncoinvent ASA
Key Statistics
Valuation
Enterprise Value
271.44M
P/E (Trailing)
‪350.00‬
PEG Ratio
‪0.65‬
Price / Sales (TTM)
‪7.66‬
Price / Book
‪4.66‬
EV / EBITDA
‪-1.62‬
Profitability
Gross Margin
‪14.83%‬
Profit Margin
‪34.25%‬
Operating Margin
‪-841.07%‬
Return on Assets
‪-94.21%‬
Return on Equity
‪-228.06%‬
Ownership
Shares Outstanding
54.71M
Float
2.44M
Held by Insiders
‪23.07%‬
Held by Institutions
‪38.69%‬
Price stats
50-Day Avg
‪0.2624‬
200-Day Avg
‪0.5130‬
Market Cap - 0RU5 - Oncoinvent ASA
Peers - 0RU5 - Oncoinvent ASA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0RU5LSEOncoinvent ASA4.59BMarket Cap+98.57%52-week change350.00P/E (Trailing)‪34.25%‬Profit Margin
- 0MGBLSEGenmab A/S198.39BMarket Cap+15.12%52-week change33.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock128.96BMarket Cap+20.00%52-week change0.53P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.95.05BMarket Cap+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.79.08BMarket Cap+20.99%52-week change0.11P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE49.68BMarket Cap+27.60%52-week change40.07P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA41.70BMarket Cap-23.88%52-week change120.47P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0RU5 - Oncoinvent ASA
About
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
